EYLEA® (aflibercept) 8 mg
Neovascular (wet) age-related macular degeneration (nAMD)
CONFIDENCE IN YOUR CHOICE WITH EYLEA® (aflibercept) 8 mg
Give your eligible nAMD patients up to 6 months between treatment visits through fast and sustained drying, with 4x the molar dose of a tried-and-tested molecule.
- Mean CRT reductions in the EYLEA 8 mg 8q12 and 8q16 arms (PULSAR) were −123.1 µm and −128.0 µm 4 weeks after 1 dose and reduction was maintained through Weeks 96–156.
EYLEA 114.3 mg/mL is indicated in adults for the treatment of neovascular (wet) age-related macular degeneration (nAMD), visual impairment due to diabetic macular oedema (DMO) and visual impairment due to macular oedema secondary to retinal vein occlusion (branch, central and hemiretinal RVO).
Optimise vision with fewer injections than EYLEA 2 mg (PULSAR)
- Lasting vision gains through Week 156
- As few as 10 injections over 3 years
Achieve fast and sustained drying to extend intervals with confidence
- Superior fluid resolution by Week 16 vs EYLEA 2 mg
- Earlier fluid‑free status vs EYLEA 2 mg (post‑hoc analysis)*
- Sustained drying through Week 156
- ~1 in 4 patients last assigned to Q24 at Week 156
Flexibly switch to EYLEA 8 mg, with or without reloading‡
- Patients with stable visual and/or anatomic outcomes can maintain or extend previous treatment intervals after the first injection of EYLEA 8 mg†
- Patients with suboptimal visual and/or anatomic outcomes may start with 1 injection per month of EYLEA 8 mg for up to 3 consecutive doses‡
*Median time to fluid-free central subfield is from a PULSAR post hoc analysis and results should be interpreted with this limitation in mind.
†Stable patients switching to EYLEA 8 mg do not require loading doses and can maintain or extend previous treatment intervals after the first injection of EYLEA. For patients who have previously been treated with EYLEA 2 mg or other anti-VEGF medicinal products and are switching to EYLEA 8 mg, the treatment regimen can differ from that used for treatment-naïve patients. Treatment intervals should be determined based on visual and/or anatomic outcomes: in patients with stable visual and/or anatomic outcomes, previous treatment intervals can be maintained or extended after the first injection of EYLEA 114.3 mg/mL, such as with a T&E dosing regimen; in patients with suboptimal visual and/or anatomic outcomes, treatment with EYLEA 8 mg may begin with 1 injection per month for up to 3 consecutive doses followed by adjustment of injection intervals, such as with a T&E dosing regimen. Consult the SmPC for full posology.
‡Following 3-monthly loading doses, intervals can be extended to Q16, dependent on visual and/or anatomic outcomes, and subsequently to 6 months (e.g. with a T&E regimen) if visual and/or anatomic outcomes are stable.
PULSAR
Optimise vision whilst minimising burden
Primary endpoint: mean change in BCVA from baseline to Week 48 (non-inferiority) with an optional 1-year open-label extension until Week 156
In PULSAR, lasting BCVA gains from baseline were non-inferior with EYLEA 8 mg vs EYLEA 2 mg and maintained through Week 156, with as few as 10 injections over 3 years*
*Includes 3 initial monthly doses.
†eFAS, observed cases.
Extend treatment intervals for eligible patients in your nAMD clinic
At Week 156, >8 in 10 patients in the EYLEA 2Q8→8 mg group achieved a last completed dosing interval of ≥Q12 at Week 156, within a year of switching (PULSAR)*
Could having more patients reach longer intervals help streamline your clinic?
*Patients completing Week 156: 8Q12/8Q16 n=375; 2Q8→8 mg n=186.
Extend treatment intervals for eligible patients across your nAMD clinic
At Week 156, approximately one quarter of patients on EYLEA 8 mg (8Q12/8Q16) achieved a last assigned dosing interval* of Q24 (PULSAR)
eSAF, patients completing Week 156.
*Patients who were randomised to the 8Q12 or 8Q16 groups at the beginning of the PULSAR study and continued treatment with EYLEA 8 mg through the PULSAR extension study Week 156; patients misassigned are included here for completeness.
†Values may not add up to 100% due to rounding.
‡One patient had a missing value for this assessment.
§Per protocol, patients in the 2Q8→8 mg group did not have sufficient time to complete a ≥Q20 treatment interval by Week 156; values may not add up to 100% due to rounding.
Abbreviations
2Q8, 2 mg every 8 weeks; 8Q12, 8 mg every 12 weeks; 8Q16, 8 mg every 16 weeks; AE, adverse event; APTC, Anti-Platelet Trialists’ Collaboration; BCVA, best-corrected visual acuity; CRT, central retinal thickness; DMO, diabetic macular oedema; DRM, dose regimen modification; E-DRM, extension phase dose regimen modification; eFAS, extension phase full analysis set; eSAF, extension phase safety analysis set; ETDRS, Early Treatment of Diabetic Retinopathy Study; FAS, full analysis set; IOI, intraocular inflammation; IOP, intraocular pressure; IRF, intraretinal fluid; LOCF, last observation carried forward; LS, least squares; nAMD, neovascular (wet) age-related macular degeneration; N-BL, new baseline; Q8, every 8 weeks; Q16, every 16 weeks; Q20, every 20 weeks; Q24, every 24 weeks; SAE, serious adverse event; SD, standard deviation; SmPC, Summary of Product Characteristics; SRF, subretinal fluid; T&E, treat and extend; TEAE, treatment-emergent adverse event; VEGF, vascular endothelial growth factor.
PP-EYL-GB-3107 | March 2026